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Introduction {#sec001}
============

Nonmelanoma skin cancer (NMSC) is the most common cancer in humans and its incidence has risen dramatically \[[@pone.0223341.ref001]\]. Approximately 20% of nonmelanoma skin cancers are cutaneous squamous cell carcinomas (cSCC). cSCC is by far the most common cancer with metastatic potential in white populations and there is a progressive increase of cSCC incidence with no tendency for levelling off \[[@pone.0223341.ref002]--[@pone.0223341.ref004]\]. Following the classical model of multistage carcinogenesis, cSCC is usually manifested as a spectrum of lesions of progressive malignancy. Actinic keratosis (AK), which consists in intraepidermal squamous neoplasms, is considered as cSCC precursor but its rate of malignant transformation is unknown. Once developed, the course of carcinoma consists in a local progression through the invasion of deep structures, regional extension by perineural or lymphatic invasion and the development of distant metastasis by vascular invasion. However, very few cases of cSCC reach advanced stages and the factors associated with rapid progression are unknown. In fact, most cSCCs have a good prognosis \[[@pone.0223341.ref005]\]. Nevertheless, there is a subgroup of SCC coined as high-risk cSCC associated with a higher frequency of local recurrence, lymph node metastasis and significant morbidity and mortality due to patient factors and features of the primary lesion. Risk stratification is critical to the management of cutaneous cSCC because it helps identify patients at high risk of poor outcomes. Although significant progress has been made in defining the clinic and pathologic factors associated with high-risk cSCC, identifying exactly which patients have a higher risk of recurrence, progression, metastasis, and death is not straightforward with these tools \[[@pone.0223341.ref006]\].

Genetic and genomic studies along the last decade have provided clues on the mutational landscape of cSCC \[[@pone.0223341.ref007]--[@pone.0223341.ref009]\]. However, the existence of a very high burden of mutation in cSCC, greater than in other solid tumours, makes difficult to identify the precise genetic events and number of mutations required for squamous cell carcinogenesis \[[@pone.0223341.ref010]\]. Alterations in the *p53* gene are the most common genetic abnormalities found in AK and invasive cSCC, and deregulation of p53 pathway appears to be an early event in carcinogenesis of cSCC \[[@pone.0223341.ref011], [@pone.0223341.ref012]\]. Other molecular alterations in the cell cycle and proliferation regulatory circuit have been identified in cSCC such as loss-of-function mutations in Notch \[[@pone.0223341.ref008], [@pone.0223341.ref009], [@pone.0223341.ref013]\] and TFGβ receptors \[[@pone.0223341.ref014]\], upregulated MAPK \[[@pone.0223341.ref015]\], amplification of the *c-Myc* locus \[[@pone.0223341.ref016]\], activating mutations of *ras* \[[@pone.0223341.ref008], [@pone.0223341.ref009], [@pone.0223341.ref017]\], aberrant activation of tyrosine kinases EGFR \[[@pone.0223341.ref018]\] and Fyn \[[@pone.0223341.ref019]\], inactivation of inositol polyphosphate 5′-phosphatase, a negative regulator of PI3K/Akt signalling \[[@pone.0223341.ref020]\]~~,~~ as well as reduced expression of PKCδ \[[@pone.0223341.ref021]\] and p16^INK4a^ p14^ARF^ tumour suppressors \[[@pone.0223341.ref022]\]. Despite the notable number of genetic studies, the results do not explain the complexity and evolution of the disease. In particular, there is a weak knowledge of the molecular risk factors associated with the high-risk aggressive subtype of cSCC in immunocompetent patients before metastatic events.

Epigenetics, as an emerging field that provides a plausible link between the environment and alterations in gene expression, may be useful to unravel the molecular mechanisms involved in the pathophysiology of this disease \[[@pone.0223341.ref023]\]. DNA methylation is a particular mechanism of epigenetic regulation that implies a covalent epigenetic modification of cytosines within CpG dinucleotides established and maintained by DNA methyltransferases. The deregulation of the methylome is a hallmark of the development and progression of human cancers \[[@pone.0223341.ref024]\] and the altered DNA methylation patterns can be used as biomarkers for tumour detection, diagnosis and prognosis \[[@pone.0223341.ref023], [@pone.0223341.ref025]\]. In the case of cSCC, previous studies targeting specific genes have reported promoter hypermethylation associated with the disease in genes such as the cell cycle regulator CDKN2A \[[@pone.0223341.ref022]\], cadherin CDH1 \[[@pone.0223341.ref026], [@pone.0223341.ref027]\] and CDH13 \[[@pone.0223341.ref028]\], transcription factor FOXE1 \[[@pone.0223341.ref029]\], modulators of Wnt signalling SFRPs \[[@pone.0223341.ref030]\] and FRZB \[[@pone.0223341.ref031]\], positive regulators of apoptosis ASC \[[@pone.0223341.ref032]\], G0S2 \[[@pone.0223341.ref033]\] and DAPK1 \[[@pone.0223341.ref034]\], and miRNA-204 \[[@pone.0223341.ref035]\], as well as hypomethylation of the DSS1 gene \[[@pone.0223341.ref036]\]. However, both DNA hypermethylation and hypomethylation associated with cancer are observed throughout the genome and these alterations, in particular the loss of methylation, may have functional consequences beyond regulation of proximal genes \[[@pone.0223341.ref024]\]. Due to this, a global vision of epigenetic regulation can only be obtained in large-scale approaches.

In the past decade, the advent of genome-scale analysis techniques, such as Infinium microarray systems, has revolutionized the field and has opened up the new era of epigenomics. These large-scale approaches have been critical to significantly improve our molecular understanding of multiple diseases and enable potential key insights for developing epigenetic therapies \[[@pone.0223341.ref037], [@pone.0223341.ref038]\]. It has been described the existence of widespread blocks of hypomethylation associated with chronic exposure in older, sun-exposed nonmalignant skin that are maintained in cSCC samples \[[@pone.0223341.ref039]\]. More recently, it was reported that both AK and cSCC methylation patterns display classical features of cancer methylomes when compared to normal skin; however, no differences between AK and cSCC were detected \[[@pone.0223341.ref040]\]. Here, we use the last generation Infinium MethylationEPIC BeadChips 850K to interrogate DNA methylation changes in the progression from premalignant actinic keratosis to invasive cSCC, differentiating low-risk and high-risk tumours. The results allowed us to identify methylation signatures able to discriminate between progressive squamous cell carcinoma stages and to provide a prognostic prediction model for disease survival.

Materials and methods {#sec002}
=====================

Patient samples {#sec003}
---------------

The patient samples comprised of 23 skin biopsies from 23 participants diagnosed at the four different stages of cutaneous squamous cell carcinoma (cSCC): actinic keratosis, early invasive carcinoma, high-risk non-metastatic carcinoma and high-risk carcinoma with nodal metastasis ([S1 Table](#pone.0223341.s002){ref-type="supplementary-material"}). The TNM classification of cSCC was evaluated according to the AJCC (American Joint Committee on Cancer) Cancer Staging Manual (8th edition) \[[@pone.0223341.ref041]\]. All the patients and samples were recruited from the Departament of Dermatology of the Instituto Valenciano de Oncología (IVO) in Valencia (Spain) after approval by the ethics committee of IVO. Written informed consent for the use of tissue samples was obtained from all included patients or their legal guardians. All research was performed in accordance with relevant guidelines and regulations. The samples were obtained from exposed skin areas from immunocompetent patients. The biopsies were obtained directly from the cSCC tumours at the time of diagnosis by surgical excision of 100--150 mg and stored as fresh frozen tissue, prepared and supplied by the Biobank at IVO. In the case of patients with actinic keratosis, a shave biopsy of the entire lesion was obtained. The samples were divided into two parts, one part being sent to pathology for confirmation of the diagnosis and the other sent for freezing. To carry out the study we proceeded to separate the dermis and epidermis, avoiding the inclusion of dermal parts. This study included only samples of actinic keratosis where a sufficiently large area of epidermal layer could be dissected. In the case of invasive carcinomas, a punch biopsy of the most representative central portion of the tumour was obtained. All samples were evaluated visually by a trained dermatopathologist to validate tumour cellularity. Tumour cells represent around the 80%-90% of total cells in most of the samples with no bias between sample groups.

DNA extraction {#sec004}
--------------

Genomic DNA (gDNA) was extracted from the frozen tissues of the cSCC samples using the QIAcube from Qiagen^®^ and the QIAamp^®^ DNA Investigator Kit (Qiagen^®^, Germany), according to the manufacturer´s protocol. Prior to performing the methylation studies, a DNA integrity quality control was performed to ensure that the DNA met the standard quality measurements that included a minimum requirement of 200 ng. All DNA samples were treated with RNaseA for 1 h at 45°C, quantified by the fluorometric method (Quant-iT PicoGreen dsDNA Assay, Life Technologies, CA, USA), and assessed for purity by NanoDrop (Thermo Scientific, MA, USA) 260/280 and 260/230 ratio measurements. DNA integrity of the fresh frozen samples was checked by electrophoresis on a 1.3% agarose gel.

Epigenomic studies {#sec005}
------------------

Epigenomic studies were performed with the Infinium MethylationEPIC BeadChips 850K array (Illumina Inc. USA) used for the interrogation of over 850,000 CpG sites (dinucleotides that are the main target for methylation), which has been previously established as a reliable technology to detect epigenetic alteration \[[@pone.0223341.ref042]\]. 600 ng of purified DNA were randomly distributed on a 96-well plate and processed using the EZ-96 DNA Methylation kit (Zymo Research Corp., CA, USA) following the manufacturer\'s recommendations for Infinium assays. The efficiency of bisulfite conversion reaction was checked, being optimal in all the cases with no significant difference between sample groups. Bisulfite-converted DNA (bs-DNA) was processed as previously described \[[@pone.0223341.ref043]\]. DNA MethylationEPIC beadarray shares the Infinium HD chemistry Assay (Illumina Inc. USA) used to interrogate the cytosine markers with HumanMethylation450 beadchip. Thus, the applicable protocol for MethylationEPIC is the same as for HumanMethylation450, which is the Infinium HD Methylation Assay Protocol. 4 μl of tissue bisulfite-DNA was processed following the Illumina Infinium HD Methylation Assay Protocol, as previously described \[[@pone.0223341.ref043]\].

The methylation score for each CpG was represented as a beta value according to the fluorescent intensity ratio. Beta values may take any value between 0 (non methylated) and 1 (completely methylated). The raw data (IDAT files) were normalized using functional normalization as implemented in the R-package minfi (version 1.22.1). CpG markers present on Methylation EPIC are classified based on its chromosome location and the feature category gene region as per UCSC annotation (TSS200, TSS1500, 5′UTR, 1st Exon, Body, 3′UTR). This array has a complete coverage of the genome including 99% of genes described. Additional criteria included the location of the marker relative to the CpG substructure (island, shore, shelf, open sea), fantom 5-associated enhancer regions and regulatory regions described on ENCODE project, such as transcription binding site sequences, open chromatin regions and DNase I hypersensitivity clusters.

Prefiltering {#sec006}
------------

Every beta value in the EPIC array is accompanied by a detection p-value which represents the confidence of a given beta value. Probes and sample filtering involved a two-step process in which unreliable betas with high detection P value P \> 0.01 (2220 CpGs) and 2932 CpGs associated with SNPs were removed. Previous analyses indicated that a threshold value of 0.01 allows a clear distinction to be made between reliable and unreliable beta values \[[@pone.0223341.ref044]\]. Sex chromosome probes were also removed (19681 CpGs). After the filtering, the remaining 841818 CpGs were considered valid for the study.

Statistical analysis {#sec007}
--------------------

Two different approaches to assess differential methylation between the different studied groups were followed. First a multinomial elastic net penalized regression was used. Penalized regression methods consist in fitting a regression model subject to a specific restriction (a bound on the value of the coefficients). This method forces the shrinkage of the parameters to zero, potentially performing variable selection at the model-fitting step \[[@pone.0223341.ref045]\]. Penalization factor for the Elastic Net was selected using 500 repetitions of 10-fold cross-validation. From each repetition the highest lambda at one standard error from the minimum was selected (one-standard-error rule) and the median of the 500 lambda values was used as the final penalization factor. CpGs with coefficients different from zero after the penalization were considered as selected by the analysis. Additionally, a beta regression model was also adjusted for each CpG with each methylation value as response variable and the variable group as predictor \[[@pone.0223341.ref046]\]. P values of the beta regression analyses were adjusted for multiple comparisons by using False Discovery Rate. A prognosis model for survival was adjusted using an elastic net penalized cox regression model. Gene Ontology (GO) analysis was performed using *ShinnyGO* \[[@pone.0223341.ref047]\] with the results of the differential methylation analysis between low-risk initial invasive and high risk non-metastatic and metastatic cutaneous squamous cell carcinoma (cSCC) stages. All statistical analyses were performed using R (version 3.5.1) and R packages *glmnet* (version 2.0--13) and *betareg* (version 3.1--0).

Results {#sec008}
=======

Description and classification of multistage cutaneous squamous cell carcinoma patient samples {#sec009}
----------------------------------------------------------------------------------------------

A critical point in this type of studies is the careful selection and classification of samples at different stages of the evolution of the pathology. In this work the classification is based on the Cancer Staging Manual 8th Edition of the American Joint Committee on Cancer (AJCC) \[[@pone.0223341.ref041]\], which distinguishes cSCC stages based on the presence or absence of several high risk-features such as the presence of significant perineural invasion, invasion of the tumour beyond subcutaneous fat or depth greater than 6mm and presence of bone involvement. The final cohort included patients with precursors of squamous cell carcinoma (actinic keratosis group) and patients with cSCC at different stages. Among the latter, we distinguish between carcinomas in the early stages of the disease (low-risk initially invasive cSCC group) defined by the absence of high risk features (T1 and T2 stages of AJCC-8) and cases at more advanced stages of the disease defined by the presence of high risk features (T3 and T4 stages of AJCC-8), differentiating those without nodal metastasis at the time of diagnosis (high-risk non metastatic group) from those with nodal metastasis (high-risk metastatic group). Long follow-up of all the cases is available to confirm the actual stage of the disease, and the overall survival. The patient characteristics are summarized in [S1 Table](#pone.0223341.s002){ref-type="supplementary-material"}.

Global DNA methylation profile in multistage cutaneous squamous cell carcinoma {#sec010}
------------------------------------------------------------------------------

In this work, we aimed to determine the overall genome DNA methylation profile in human skin from pre- and post-malignant multistage cSCC using the Infinium DNA Methylation EPIC BeadChip microarray 850K (Illumina), in order to investigate the existence of potential elements of distinction among specific stages of carcinoma development. In a first approach, an exploratory principal component analysis (PCA) revealed a separation among the clusters associated with the four analysed groups ([Fig 1A](#pone.0223341.g001){ref-type="fig"}). In particular, the results suggest that major transitions in methylation pattern occur between actinic keratosis, low-risk initial invasive carcinoma stage and high-risk carcinoma stages, with small differences associated with the presence or not of metastasis.

![Analysis of the global DNA-methylation profile in multistage cSCC.\
*A)* Representation of the Principal Component Analysis (PCA) on the methylation data. Centroids of each group of patients are represented by different shapes and colors (legend indicated in B). *B)* Heatmap with a random sample of 5000 CpGs from the results of the beta regression analysis for differential methylation among all cutaneous squamous cell carcinoma groups of patients. Z-score colour scale ranges from green for lower methylation to red for higher methylation levels.](pone.0223341.g001){#pone.0223341.g001}

We wondered if DNA methylation alterations in cSCC occur sequentially throughout the different stages of skin tumour. To investigate this point, we performed a penalized ordinal regression including all CpGs as potential predictors. However, no ordinal association was found. This indicates that no evident sequential DNA methylation changes occur in the development of cSCC. Next, we performed a differential methylation study using a beta regression analysis for each CpG with the group as independent variable. Using an FDR-adjusted p-value cut-off of 0.05, we found 272,964 differentially methylated CpGs among the four groups that represent 32% of the CpGs investigated ([Fig 1B](#pone.0223341.g001){ref-type="fig"}). A very high number of differentially methylated CpGs between the four groups were still detected when more stringent analysis (p-values from 10^−2^ to 10^−10^) were carried out ([S2 Table](#pone.0223341.s003){ref-type="supplementary-material"}). An initial inspection of the heatmap suggests an interesting pattern in which the methylation state decreases from actinic keratosis to low-risk initial invasive carcinoma group but increases from low risk to high risk (non-metastatic and metastatic) groups. These results reveal a massive and complex pattern in the DNA methylation evolution during the development of cSCC affecting the global epigenomic structure.

Identification of a DNA-methylation signature characterizing the different stages of cSCC {#sec011}
-----------------------------------------------------------------------------------------

In order to identify the minimum number of CpGs characterizing the distinct groups, we performed an elastic net penalized multinomial logistic regression with stage as response variable and all CpGs as potential predictors of epigenetic changes able to discriminate among groups. Interestingly, the results of this model showed that a profile consisting of only 94 CpG was enough to correctly classify 100% of the samples. The results of this supervised analysis are depicted in a clustered heatmap ([Fig 2](#pone.0223341.g002){ref-type="fig"}) and presented in [S3 Table](#pone.0223341.s004){ref-type="supplementary-material"}. Strikingly, the heatmap of these CpGs suggested that, on one hand, the initial invasive group showed lower methylation levels than premalignant actinic keratosis, and on the other hand, high-risk non-metastatic and metastatic groups displayed higher methylation levels. This confirms the existence of a non-sequential and complex pattern of DNA-methylation during cSCC evolution. Importantly, we have generated an epigenetic model based on genome wide profiling that may classify prospective samples based on the methylation level of 94 CpGs.

![Identification of a DNA-methylation signature characterizing the different stages of cSCC.\
Heatmap with the results of the elastic net analysis for discrimination among all cutaneous squamous cell carcinoma groups of patients. Rows (CpGs) and columns (individuals) are ordered according to the results of a hierarchical clustering algorithm. Z-score colour scale ranges from green for lower methylation to red for higher methylation levels.](pone.0223341.g002){#pone.0223341.g002}

Additionally, we performed a technical validation of the signature, by carrying out a pyrophosphate sequencing with 5 CpGs representative of the 94 CpGs. The results validated the discrimination power of the signature, since the pyrosequencing data was able to correctly classify 82% of the samples (18 out of 22) and achieved a weighted Bangdiwala score of 0.90 \[[@pone.0223341.ref048]\]. The representation of the confusion matrix as an agreement plot is included as [S1 Fig](#pone.0223341.s001){ref-type="supplementary-material"}.

Comparison of DNA-methylation pattern between low-risk and high-risk stages {#sec012}
---------------------------------------------------------------------------

To better differentiate between cSCC stages depending on the risk, a new elastic net penalized multinomial logistic regression analysis was performed to compare low-risk initial invasive cSCC patients to high-risk non-metastatic and metastatic cSCC patients. Given the small differences we observed in the PCA analysis between the two latter groups of samples (see [Fig 1A](#pone.0223341.g001){ref-type="fig"}) and previous reported analysis indicating that there is not widespread differences in the methylation patterns between non-mestastatic versus metastatic cSCC \[[@pone.0223341.ref031]\], the high-risk non-metastatic and metastatic samples were considered as a single group in this analysis in order to optimize the output. The results revealed 637 differentially methylated CpGs ([Fig 3A](#pone.0223341.g003){ref-type="fig"} and [S4 Table](#pone.0223341.s005){ref-type="supplementary-material"}) between low-risk and high-risk cSCC. Most of them (602 CpGs) represent a gain of methylation in high-risk versus low-risk stages, whereas the minority of cases (35 CpGs) present a loss of methylation in high-risk versus low-risk stages. Thus, and consistent with the analysis showed above, the low-risk invasive group also showed lower median methylation levels than high-risk groups ([Fig 3B](#pone.0223341.g003){ref-type="fig"}). In conclusion, there is a risk-dependent change in DNA methylation patterns, mostly indicating a gain of methylation.

![Comparison of DNA-methylation pattern between low-risk and high-risk stages.\
*A)* Heatmap with the results of the elastic net analysis for differential methylation between low-risk initial invasive and high risk non-metastatic and metastatic cutaneous squamous cell carcinoma (cSCC) stages. Z-score colour scale ranges from green for lower methylation to red for higher methylation levels. *B)* DNA methylation median β-values of the different epigenomic substructures in the different groups of sCCC. Box plots indicate highly significant (p \< 0.001, two-sided t-test) hypermethylation of all substructures in both high-risk non-metastatic and metastatic groups compared to low-risk initial invasive cSCC samples. *C)* Distribution of selected differentially methylated CpGs in high-risk compared to low-risk cSCC (hypomethylated in green and hypermethylated in red) and total CpG in the Illumina DNA methylation EPIC array in genes, promoters, gene body or intergenic regions. *D)* Distribution of differentially methylated CpGs in CpG islands, shore, shelf or open sea.](pone.0223341.g003){#pone.0223341.g003}

Next, the distribution of the identified CpGs with gain and loss of methylation between high-risk versus low-risk stages, was analysed in the Illumina EPIC array regarding functional genomic distribution (FGD) ([Fig 3C](#pone.0223341.g003){ref-type="fig"}) and CpG substructure context ([Fig 3D](#pone.0223341.g003){ref-type="fig"}). Regarding FGD, CpGs with gain of methylation were preferentially found in the gene body whereas CpGs with loss of methylation were enriched in the promoter regions ([Fig 3C](#pone.0223341.g003){ref-type="fig"}). Notably, based on CpG substructure context, the distribution of CpGs with gain of methylation revealed a significant enrichment in open sea (low density CpG regions), while CpGs with loss of methylation were mainly found in CpG shores ([Fig 3D](#pone.0223341.g003){ref-type="fig"}). Strikingly, CpGs located in CpG islands (high density CpG regions) were underrepresented in both cases.

Finally, the functional signature of the genes associated with DNA methylation changes was investigated with the ShinnyGO data set \[[@pone.0223341.ref047]\]. 395 out of the 454 genes with altered CpG methylation were classified based on Biological Process categories. The detected enriched categories using a p-value cutoff of 0.01 are shown in [Fig 4](#pone.0223341.g004){ref-type="fig"} and [S5 Table](#pone.0223341.s006){ref-type="supplementary-material"}. Interestingly, this analysis revealed that genes with changes in CpG methylation are mainly associated with categories that are directly related to cancer, such as signal transduction and cell motility, as well as phospholipid metabolic processes. Further analysis of KEGG (Kyoto Enciclopedia of Genes and Genomes) pathways \[[@pone.0223341.ref049]\] showed an enrichment in key signalling pathways related to cell proliferation and cell fate like Notch, hedgehog, MAPK, TFGβ and Wnt pathways ([S6 Table](#pone.0223341.s007){ref-type="supplementary-material"}).

![Analysis of genes associated to differentially methylated CpG between low-risk and high-risk stages.\
Hierarchical clustering tree of the enriched gene sets obtained from the GO analysis of the genes selected in the comparison between low-risk initial invasive and high risk non-metastatic and metastatic cutaneous squamous cell carcinoma (cSCC) stages.](pone.0223341.g004){#pone.0223341.g004}

Prognosis signature {#sec013}
-------------------

Finally, we attempted to produce a prognostic prediction model for overall survival in cSCC patients. To do this, a penalized cox regression model using all CpGs as potential predictors was adjusted. The adjusted elastic net model selected a specific signature of 32 CpGs ([S7 Table](#pone.0223341.s008){ref-type="supplementary-material"}) able to predict risk of death in these patients with a very high discriminant capacity (Area under the curve, AUC = 0.98). This discrimination capacity was represented using model-estimated survival curves showing that patients with a higher predicted risk had a markedly shorter survival time compared to patients with a lower predicted risk ([Fig 5](#pone.0223341.g005){ref-type="fig"}). Thus, the analysis of the methylation status of these 32 CpGs emerges as a good approach to predict the evolution of the disease.

![Survival model based on a prognosis DNA-methylation signature.\
Representation of the predicted survival curves in patients with cSCC for different estimated risk values by the regression model using 32 CpGs. Patients with higher predicted risk levels show sizeably lower overall survival (OS) in comparison with patients with lower predicted risk levels.](pone.0223341.g005){#pone.0223341.g005}

Discussion {#sec014}
==========

In recent years, epigenetics has become a discipline capable of explaining some aspects of different pathologies. In particular, it has shed light on the evolution of different types of cancer \[[@pone.0223341.ref024]\]. cSCC is a major type of skin cancer with an increasing incidence. However, it has been less studied than other skin cancers and there is not a definitive description of its genetic and epigenetic bases. In this context, this work tried to analyse the epigenetic phenomena underlying the evolution of the pathology.

cSCC is a particular type of cancer in which tumour cells accumulate a big amount of genetic alterations due to chronic exposure to sun radiation\[[@pone.0223341.ref010]\]. It has been hypothesized that ultraviolet radiation in natural sunlight may promote tumorigenesis not merely due to DNA damage, but also through induction of epigenetic dysregulation. Consistent with this, previous reports have described that aberrant DNA-methylation patterns related to cSCC, when compared to healthy skin, seems to involve vast changes encompassing a large proportion of the genome \[[@pone.0223341.ref039], [@pone.0223341.ref040]\]. Thus, cSCC is associated with massive alterations of both genetic and epigenetic traits. We have now identified that an enormous amount of CpG shows significant changes between the different stages of the disease. This indicates that the massive epigenetic alterations associated with cSCC is not just a stationary terminal characteristic of tumour cells; rather, enormous changes are dynamically occurring along the evolution of the disease through their different stages. Surprisingly, it seems to exist a non-sequential pattern of DNA-methylation changes during cSCC evolution. What it is clear when the comparison is restricted to low-risk against high-risk samples, is that malignancy is associated to a higher DNA-methylation level. It is tempting to speculate that evolution from premalignant actinic keratosis could follow alternative pathways to evolve to a low-risk stage when DNA-methylation is lowered or a high-risk stage when DNA-methylation is increased. In fact, clinical analysis of patients reveals that not all high-risk cSCC have necessarily passed through a low-risk stage. On the other hand, our results demonstrate that the different stages of cSCC present indeed specific DNA-methylation characteristics that allow to distinguish them. In fact, a minimal epigenetic signature that provides a powerful tool to discriminate between the different stages was obtained using DNA-methylation information from only 94 CpGs. This signature could be useful to classify prospective samples.

From a clinicopathological point of view, the most interesting aspect is the ability to distinguish between a low-risk and a high-risk stage. A direct comparison of these groups provides evidence for the existence of considerable changes in the DNA methylation pattern that are associated with a worse tumour evolution. In fact, 637 differentially methylated CpGs were identified. In 95% of cases, the change implies a hypermethylation of CpGs in the high-risk samples. A recent study suggested that UV-irradiation through chronic sun exposure gives rise to large hypomethylated blocks in healthy epidermis \[[@pone.0223341.ref039]\]. In view of our results, it is tempting to speculate that DNA-hypomethylation caused by sun exposure characterizes the premalignant and low-risk stages of cSCC and that the evolution to more advanced stages of worse prognosis occurs when the state of methylation is reversed changing from hypo to hypermethylated DNA.

Specific changes in gene function related to cell proliferation, cell fate and cell motility could be epigenetically controlled in the transition from low-risk to high-risk stage. DNA methylation could affect gene function in different ways \[[@pone.0223341.ref024], [@pone.0223341.ref050]\]. The methylation state of a promoter affects gene expression, DNA hypermethylation resulting in gene silencing. Also, DNA methylation increases the mutation rate and tumours tend to be globally hypomethylated, which generally results in genomic instability. In our analysis, CpGs with gain of methylation are preferentially found in the gene body whereas CpGs with loss of methylation were enriched in the promoter regions. It can be speculated that, overall, the loss of methylation in promoters could lead to increased expression of key genes and that hypermethylation in body regions could increase the mutation rate. Regarding the CpG substructure, it is surprising that CpG islands were underrepresented in the group of differentially methylated CpGs between low-risk and high-risk stages. Nevertheless, other authors have also pointed out the relevance of methylation changes in open seas and shores in aged sun-exposed skin and cSCC \[[@pone.0223341.ref039], [@pone.0223341.ref040]\], as occurs in other cancers \[[@pone.0223341.ref051]\]. Thus, the major changes in the methylome during the development of cSCC does not seem to occur in CpG islands.

Interestingly, the GO analysis of the genes associated with differentially methylated CpG between low-risk and high-risk stages, indicates an enrichment of genes in categories directly involved in cancer development like signal transduction and cell motility. In particular, it has to be noted that the number of genes related to signal transduction that manifested an alteration in their DNA-methylaton pattern is of 119 ([S5 Table](#pone.0223341.s006){ref-type="supplementary-material"}); this suggest that the transition to a high-risk state of the disease could be caused by a collection of dysfunctions in several signalling processes controlling cell behaviour. In fact, the KEGG analysis identifies important signalling pathways like MAPK, Notch, Wnt, TFGβ and hedgehog pathways, as potential pathways missregulated in the transition to a high-risk stage. It is important to remark that epigenetic alterations in other genes related to the Wnt-signalling pathway had been previously reported in cSCC samples \[[@pone.0223341.ref030], [@pone.0223341.ref031]\], as well as genetic mutation in Notch receptors \[[@pone.0223341.ref008], [@pone.0223341.ref009], [@pone.0223341.ref013]\]; our results support a broad extension of epigenetic alterations in the Wnt pathway and point to a combination of genetic and epigenetic alterations in the deregulation of the Notch pathway in cSCC.

Very recently, other authors reported a study of the DNA-methylome in cSCC \[[@pone.0223341.ref039], [@pone.0223341.ref040]\]. They report that both AK and cSCC methylation patterns display classical features of cancer methylomes. Importantly however, and in contrast to our results, no differences in the methylation profile between these stages of the pathology were identified using linear regression methods. A big difference between Rodriguez-Paredes et al. analysis and our analysis is that Rodriguez-Paredes et al. only considered two groups of samples, premalignant AK and tumour samples, independently of the stage of evolution of cSCC. As commented above, we have detected a complex non-linear evolution of the DNA-methylation pattern during the development of cSCC, so it is possible that a low-stringent classification of samples could mask the detection of changes. To address the potential conflict between both studies, we performed an analysis on our dataset including our three cSCC subgroups (low-risk initial invasive, high risk non metastatic and metastatic) as one single group and compared this group against the actinic keratosis group. The results were completely in agreement with those of Rodriguez-Paredes et al, finding no significant differences between the actinic keratosis patients and all-grouped cSCC patients. This result confirmed that disregarding the non-sequential epigenetic pattern among the different cSCC subgroups results in an inability to detect epigenetic alterations, since DNA methylation gain/loss among cSCC subgroups could be compensated and cancelled.

Finally, a prognostic prediction model was developed. Histopathology and immunohistochemistry, the standard methods for cancer diagnosis, have important limitations since they are time consuming and the result depends on a pathologist's subjective interpretation. Due to this, there is a need for molecular biomarkers that could be useful in tumour diagnosis and grading and with a potential use in prognosis of the disease. In this sense, we have identified a signature based on the methylation state of 32 CpGs that provides a risk-score, which is associated with the overall survival of the patients. Notably, one of these CpGs is located in the gene coding for p73, a functional homolog of p53 that has been related to cancer \[[@pone.0223341.ref052]--[@pone.0223341.ref054]\]. p53 deregulation is an early event in carcinogenesis of cSCC, so it is tempting to speculate that alteration of its functional homolog p73 could be critical for bad prognosis. Although this 32 CpG signature is a preliminary proposal, it supports the general conclusion that the analysis of the degree of methylation for DNA samples from cSCC patients can be of great value, not only in the diagnosis but also in the prognosis. The development of future tools following this basis and its validation with larger cohorts could be of important help in clinical practice.

Conclusions {#sec015}
===========

Our results showed massive non-sequential changes in DNA-methylome along the different cSCC stages, identified a minimal methylation signature that discriminates between stages and revealed epigenetic traits characteristic of high-risk tumours. In addition, a prognostic prediction model in cSCC patients identified a methylation signature able to predict the overall survival of patients. Thus, we conclude that DNA-methylation information can be of great value in the diagnosis and the prognosis of cSCC.

Supporting information {#sec016}
======================

###### Technical validation of the 94CpG signature by pyrophosphate sequencing of 5 representative CpG.

Graph represents the agreement plot derived from providing visual assessment of agreement between observed and predicted values from pyrosequencing data of 5CpG in our cohort as described in Bangdiwala et al. 2008, *Journal of Clinical Epidemiology* 61:866--874. Shaded areas represent cell frequencies from the confusion matrix of the adjusted multinomial model. The degree of agreement is visually expressed by the proportion of area in the darkened squares compared with the total area defined by the row and column marginal totals. A: actinic keratosis; B: low-risk cSCC; C: high-risk non metastatic cSCC; D: high-risk metastatic cSCC. Note that only 22 out of the 23 samples described in the manuscript could be analysed in the pyrosequencing assay.

(PDF)

###### 

Click here for additional data file.

###### List of samples.

(DOCX)

###### 

Click here for additional data file.

###### Number of differentially methylated CpGs between groups.

(DOCX)

###### 

Click here for additional data file.

###### DNA-methylation signature: 94 CpGs discriminating the four groups.

(XLSX)

###### 

Click here for additional data file.

###### Differentially methylated CpGs between high-risk and low-risk carcinomas.

(XLSX)

###### 

Click here for additional data file.

###### GO categories enriched in genes associated to DM CpGs between low-risk and high-risk carcinomas.

(XLSX)

###### 

Click here for additional data file.

###### Enriched KEGG pathways.

(DOCX)

###### 

Click here for additional data file.

###### DNA-methylation prognosis signature: 32 CpGs predicting bad prognosis.

(XLSX)

###### 

Click here for additional data file.
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Dear Dr. Igual,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the points raised during the review process.

As stated in reviewers' comments, both reviewers suggested multiple improvements for the revision of the manuscript. Specifically, the Editor felt that all the CpG methylation data was obtained by only one technical platform. Thus, Editor thought that the authors should confirm their CpG methylation results of at least some representative CpG sites (especially the signature list of 32 CpGs), using other methylation analysis techniques such as bisulfite sequencing/pyro-sequencing/or methylation-specific PCR.

We would appreciate receiving your revised manuscript by Nov 28 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.
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2\. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3\. We note that you are reporting an analysis of a microarray, next-generation sequencing, or deep sequencing data set. PLOS requires that authors comply with field-specific standards for preparation, recording, and deposition of data in repositories appropriate to their field. Please upload these data to a stable, public repository (such as ArrayExpress, Gene Expression Omnibus (GEO), DNA Data Bank of Japan (DDBJ), NCBI GenBank, NCBI Sequence Read Archive, or EMBL Nucleotide Sequence Database (ENA)). In your revised cover letter, please provide the relevant accession numbers that may be used to access these data. For a full list of recommended repositories, see <http://journals.plos.org/plosone/s/data-availability#loc-omics> or <http://journals.plos.org/plosone/s/data-availability#loc-sequencing>.
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**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: A methylation profiling study was performed in 23 cases using the Illumina EPIC beadchip to identify the methylation changes specific to high-risk cSCC. The samples are carefully selected and classified into 4 groups as premalignant actinic keratosis, low-risk invasive, high-risk non-metastatic and metastatic cSCC. A large number of differentially methylated CpG sites were found among 4 groups by the regression analysis. The methylation signature including 94 CpG sites to classify different stages was identified and the authors attempted to build a prediction model for overall survival in cSCC. The strength of the study is the use of carefully classified samples with detailed analysis, while the weakness is also obvious with limited number of samples. The reviewer has several major comments that need to be further clarified and addressed as below.

1\. What is the bisulfite conversion efficiency for the EPIC beachip? Are they similar among 4 groups?

2\. A large number of differentially methylated CpG sites was identified among four groups. The cellularity for these samples is not presented in the manuscript, so it is difficult to evaluate if different carcinoma contents potentially confound this analysis.

3\. The author reported that there are no sequential DNA methylation changes occur in the development of sSCC. Only 23 samples were included in the analysis. Is this sample size adequate to draw this conclusion?

4\. Considering only 94 selected CpG sites, the authors found that the methylation level is lower in the initial invasive group than premalignant actinic keratosis, while it is higher in the high-risk groups compared to the low-risk group. Does this trend also true for the global methylation level?

5\. A prognostic prediction model was established considering all CpGs as potential predictors. Again, the sample size is a limitation. The rational for establishing the prediction model is unclear. It is highly possible that the prognostic value of this signature comes from the association with stage. If it is the case, then, measurement of methylation biomarkers with additional cost does not add any clinical value in practice.

Reviewer \#2: This study investigated the DNA methylation changes in patients with different disease stages, from premalignant AK to low-risk invasive cSCC, high-risk non-metastatic and metastatic cSCC. The identified methylation signatures could discriminate different disease stages, but also predict overall survival, providing insights for the diagnosis and prognosis of this disease. However, there are several minor comments of this paper.

1\. The methylation analysis showed that the low-risk invasive cSCC exhibited lower methylation levels than premalignant AK, and high-risk non-metastatic and metastatic cSCC exhibited higher methylation levels, indicating a non-sequential and complex pattern of DNA-methylation during cSCC evolution. This is an interesting finding, the authors would be advised to discuss the possible cause of this changes.

2\. All of the data are based on microarray analysis, it is better to select several genes for MSP or pyrophosphate sequencing validation, which would support their findings and conclusions.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewer 1

We agree with the reviewer's comment regarding the limited number of samples included in the study. Obviously, in this kind of studies the more samples the better. However, we would like to emphasize that other cSCC studies with a similar strategy, that is, the use of epigenomics arrays, used a comparable number of samples. Vandiver et al Genome Biol. 2015;16:80 analyzed 7 cSCC samples, whereas Rodriguez-Paredes M et al. Nat Commun. 2018;9(1):577 characterized 16 actinic keratosis samples against 18 cSCC samples. Moreover, none of these studies classify samples in four different stages, which, as the Reviewer kindly comment, is the strength of our study.

Major comments have been addressed as follow:

1\. What is the bisulfite conversion efficiency for the EPIC beachip? Are they similar among 4 groups?

As a part of our standard protocol, we checked the bisulfite conversion reactions analyzing the BS Conversion I and BS Conversion II control probes as described in Illumina user guide. In all the samples, the efficiency of bisulfite conversion was optimal with no significant differences among sample groups. We have introduced a sentence in the Methods section (page 6) to clarify this point.

2\. A large number of differentially methylated CpG sites was identified among four groups. The cellularity for these samples is not presented in the manuscript, so it is difficult to evaluate if different carcinoma contents potentially confound this analysis.

It was mentioned in the Materials and Methods section, at the end of Patient samples block, that 'All samples were evaluated visually by a trained dermatopathologist to validate tumour cellularity'. Indeed, tumour cells in most of the samples represent around a 80%-90% of total cells, and no bias between groups was observed. This data is now included in the text (page 5) to avoid confusion.

3\. The author reported that there are no sequential DNA methylation changes occur in the development of sSCC. Only 23 samples were included in the analysis. Is this sample size adequate to draw this conclusion?

We agree with the reviewer that the statistical power is not enough to rule out the existence of specific and individual CpGs sequential changes. However, our ordinal regression analysis, which assumed changes to be sequential from actinic keratosis to high-risk metastatic cSCC, did not find any CpG able to discriminate among groups. In contrast, the multinomial regression analysis, which was not restricted by the sequential effects assumption, found clear methylation patterns discriminating among the four groups. Considering the reviewer's suggestion, we have softened the statement regarding the sequential methylation changes. Now it is stated in page 9 that: 'This indicates that no evident sequential DNA methylation changes occur in the development of cSCC.'

4\. Considering only 94 selected CpG sites, the authors found that the methylation level is lower in the initial invasive group than premalignant actinic keratosis, while it is higher in the high-risk groups compared to the low-risk group. Does this trend also true for the global methylation level?

As stated in the previous response, the statistical power is not large enough to draw strong global conclusions regarding methylation patterns, in contrast to the 94 CpG signature which clearly discriminates between the four groups and clearly shows the mentioned pattern. Nevertheless, when examining random subsamples of the whole dataset in a heatmap (Figure 1B), the pattern showed always this same behavior. This is in fact stated in the text in the first paragraph of page 10.

5\. A prognostic prediction model was established considering all CpGs as potential predictors. Again, the sample size is a limitation. The rational for establishing the prediction model is unclear. It is highly possible that the prognostic value of this signature comes from the association with stage. If it is the case, then, measurement of methylation biomarkers with additional cost does not add any clinical value in practice.

In this approach we wanted to emphasize the potential role of epigenomics not only in diagnosis but also in prognosis. We agree with the reviewer that the sample size is a limitation and further validation of this model should be performed in future studies. Nevertheless, the model was fitted with an advanced statistical method, elastic net, which is specifically suited for dealing with data sets with a large number of variables and very few observations.

Regarding the possibility of an association with stage, we assessed the capability of each of the included CpGs in the model in discriminating between the four stages. Remarkably, no CpG showed discriminative power among stages, with the lowest p-value being 0.24. Also, a cox regression model including stage as predictor showed an AUC of 'only' 0.72, compared to the AUC of 0.98 of our model including 32 CpGs. Therefore, no evidence suggests that this epigenetic signature might be confounded by stage, which reinforces its value as a potential biomarker for survival prognosis.
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Response to Reviewer 2

1\. The methylation analysis showed that the low-risk invasive cSCC exhibited lower methylation levels than premalignant AK, and high-risk non-metastatic and metastatic cSCC exhibited higher methylation levels, indicating a non-sequential and complex pattern of DNA-methylation during cSCC evolution. This is an interesting finding, the authors would be advised to discuss the possible cause of this changes.

It is not obvious the significance of this non-sequential pattern of DNA-methylation during cSCC evolution. What it is clear when the comparison is restricted to low-risk against high-risk samples, is that malignancy is associated to a higher DNA-methylation level. It is tempting to speculate that evolution from premalignant actinic keratosis could follow alternative pathways to evolve to a low-risk stage when DNA-methylation is lowered or a high-risk stage when DNA-methylation is increased. In fact, clinical analysis of patients reveals that not all high-risk cSCC have necessarily passed through a low-risk stage. This hypothesis is now commented in the Discussion section in page 14.

2\. All of the data are based on microarray analysis, it is better to select several genes for MSP or pyrophosphate sequencing validation, which would support their findings and conclusions.

We have carried out a pyrophosphate sequencing with 5 CpG of the 94 CpG signature discriminating between the four different stages. The results validated the discrimination power of the signature, since the pyrosequencing data was able to correctly classify 82% of the samples (18 out of 22) by using only 5 CpGs out of the 94 CpGs from the original signature and achieved a weighted Bangdiwala score of 0.90 out of 1 in the agreement test (Bangdiwala et al 2008,The agreement chart as an alternative to the receiver-operating characteristic curve for diagnostic tests. Journal of Clinical Epidemiology, 61 (9), 866-874). These results are now commented in the Results section in page 11 and the representation of the confusion matrix as an agreement plot is included as Supplementary Figure 1.
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Dear Dr. Igual,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses all the points raised by the reviewers.

We would appreciate receiving your revised manuscript by Jan 16 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Qian Tao

Academic Editor

PLOS ONE
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The author added a statement that \"the efficiency of bisulfite conversion reaction was checked, being optimal in all the cases with no significance difference between sample groups\". Please clearly specify what bisulfite conversion efficiency was achieved in this study.

There are some grammatical errors in the manuscript. The authors should read through the manuscript carefully and make the correction. For example, it should be 'no significant difference' instead of 'no significance difference' at line 121 on page 6; it should be 'distinguishes' instead of 'distinguish' at line 174 on page 8.

.

Reviewer \#2: The authors have addressed all my comments, I have no further comments. I recommend this paper to be pulished.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewer 1

We are extending the response regarding Reviewer's concern about bisulfite conversion since it seems it was not clearly answered. As we stated in our previous response, we checked our Illumina´s internal controls as a routine step in standard protocols in methylation analysis. The analysis of BS Conversion I and BS Conversion II control probes were in the standard parameters recommended by Illumina user guide. We provide now the graphs with this information from Illumina examples and from our experiment to be checked by the Reviewer. We hope this information helps to clarify this point. We would like to add that unless new or modified Illumina protocols are described in the studies, these Illumina´s internal controls are not usually included in manuscripts. Therefore, we have not included them in our manuscript, although we can do it if the Reviewer considers it is necessary.

This is the text that GenomeStudio® Methylation Module v1.8 User Guide indicates for bisulfite conversion controls. We would like to clarify that Illumina did not update this guide when the Infinium EPIC DNA methylation beadchip array used in this study was released. Therefore, controls in our array are quite similar but not identical to the showed in the user guide.

(SEE ATTACHED FILE FOR FIGURES)

And these are the results for our samples:

Bisulfite Conversion I controls

Bisulfite Conversion II controls

(SEE ATTACHED FILE FOR FIGURES)

Thanks for indicating the presence of grammatical errors. A native English speaker author had edited writing and now another independent native English speaker has edited it.
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PONE-D-19-25692R2

Dear Dr. Igual,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Qian Tao

Academic Editor

PLOS ONE
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Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma

Dear Dr. Igual:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Qian Tao

Academic Editor

PLOS ONE
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